Citius Oncology raises $36.5m for Lymphir commercialisation

Citius Oncology has secured up to $36.5m to accelerate the commercialisation of Lymphir, a recombinant fusion protein immune therapy. The capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m. Proceeds will fund Lymphir’s commercialisation, market access, medical affairs, and manufacturing. Credit: Gorodenkoff / Shutterstock.com. Citius Oncology has secured up to $36.5m in a combination of debt and equity financing to accelerate the commercialisation of Lymphir (denileukin diftitox-cxdl), a recombinant fusion protein immune therapy. The therapy is approved by the US Food and Drug Administration (FDA) for adult patients with relapsed or refractory Stage I-III…

Source: Pharmaceutical Technology